News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Novartis International AG Cuts Outlook; US Regulators Extend Tasigna Review
July 17, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, July 17 (Reuters) - Swiss drugmaker Novartis AG (NOVN.VX: Quote, Profile, Research) said on Tuesday that U.S. regulators had requested a three-month extension in the regulatory review period for cancer drug Tasigna.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Earnings
Europe
MORE ON THIS TOPIC
Earnings
Merck looks ahead to ‘another year of investment’ as Keytruda cliff looms
October 29, 2026
·
4 min read
·
Heather McKenzie
Earnings
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
October 29, 2026
·
4 min read
·
Gabrielle Masson
Neuroscience
Ono cans 2 endocannabinoid drug studies after quintuple Phase 2 failure
October 29, 2026
·
1 min read
·
Annalee Armstrong
Earnings
Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellers
October 29, 2026
·
1 min read
·
Annalee Armstrong
